Rosen Quoted on Interchangeability and Biosimilar Guidances

07 January 2015 BioWorld Today News

BioWorld Today

Partner David Rosen was quoted in a BioWorld Today article, “FDA: Interchangeability, Other Guidances for Biosimilars in the Works,” on January 7, 2015. The article discussed possible FDA guidance changes on interchangeability, biosimilar draft guidance on labeling, statistical approaches for analyzing similarities in data, and implications of Biologic Price Competition and Innovation Act (BPCIA).

Rosen was quoted saying, “Some of the differences of opinion may be one of the reasons the guidances are a long time in coming. For instance, concerns about the potential market impact of naming and interchangeability guidelines could subject the drafts to the interagency review process.”


Do You Know What IMMEX Stands For?
16 July 2019
Dashboard Insights
Does The U.S. Need STRONGER Patents?
16 July 2019
PTAB Trial Insights
California Establishes Fund to Combat Wildfire Threats
15 July 2019
Renewable Energy Outlook
There’s No Place Like Home – But Is That a Reasonable Accommodation?
15 July 2019
Labor & Employment Law Perspectives
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
2019 NDI Executive Exchange
14-15 November 2019
Chicago, IL
MAGI’s Clinical Research Conference
29 October 2019
Las Vegas, NV
Association for Corporate Counsel Annual Meeting 2019
27-30 October 2019
Phoenix, AZ